Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 71610-940

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 71610-940). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0940 89)

This text provides information about a medication named Sacubitril/Valsartan, along with a number sequence and alphanumeric characters. The text also mentions "BATCH 1" which could be associated with a specific batch or production code. This text seems to be a combination of product name, codes, and possibly dosage instructions.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure-1 (Sacubitril Valsartan Figure 1)

This is a list of coadministered drugs with geometric mean ratio and 90% confidence interval for each drug in relation to the reference drug. The drugs listed include furosemide, warfarin, digoxin, carvedilol, levonorgestrel, ethinyl estradiol, amlodipine, metformin, atorvastatin, and sildenafil. The text suggests a comparison of these drugs in terms of their effects when coadministered.*

FDA Label Image

Figure-2 (Sacubitril Valsartan Figure 2)

FDA Label Image

Sacubitril-valsartan-figure-3.jpg (Sacubitril Valsartan Figure 3)

The text describes a study named PARADIGM-HF that evaluates the time to first occurrence of cardiovascular death (CV) or heart failure hospitalizations. The study compares the outcomes of patients treated with Sacubitril and Valsartan against those treated with Enalapril. The text includes statistical information, hazard ratios, confidence intervals, and the number of patients at risk over time since randomization in days. It also mentions the cumulative failure rate of heart failure hospitalizations in the study. The study results indicate a significant difference in outcomes between the two treatment groups.*

FDA Label Image

Structure (Sacubitril Valsartan Structure)

FDA Label Image

Sacubitril-valsartanl-figure-4.jpg (Sacubitril Valsartanl Figure 4)

The text provides data on various subgroups related to population distribution, including age, gender, weight, race, region, NYHA Class, estimated GFR, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP, hypertension, prior medication use, hospitalization history, time since diagnosis, cause of heart failure, and the usage of medications like Sacubitril and Valsartan and Enalapril. It also includes corresponding numbers and percentages in different categories for further analysis. This information is useful for analyzing and understanding different factors related to heart failure and related treatments.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.